Federated biobank · Coming soon
A federated biobank for research collaboration.
Built on India's point-of-care clinico-genomic data. The query travels, the data never moves: each site keeps its records in place, a question runs locally at every node, and only aggregate results return. Launching soon.
Point of care → federated network → query in, results out, raw data never leaves each site.
The resource
A living, point-of-care data resource.
De-identified clinical records linked to genomic data, generated in routine care and updated continuously, not frozen at enrolment.
clinical records linked
with genomic data
hospital sites
Targets, 100,000 linked records and 10,000 genomic-linked within 24 months.
Ways to work with us
Built for research partnerships.
Bring a question; we scope a research collaboration around it.
Cohort & data discovery
Define and explore phenotyped cohorts inside the TRE, from feasibility counts to full analysis.
Register your interest →Target discovery & validation
GWAS, gene-burden and human-knockout work to find and de-risk targets in a diverse population.
Register your interest →Biomarker & endpoint studies
Discover and validate biomarkers and real-world endpoints against linked clinical outcomes.
Register your interest →Real-world evidence
Link genomes to longitudinal outcomes for safety, efficacy and HEOR questions.
Register your interest →Sponsored cohort generation
Co-design and sequence a bespoke cohort to your inclusion criteria.
Register your interest →Bespoke research
Joint studies and custom data generation, scoped to your programme.
Register your interest →Priority cohorts
The cohorts we're building first.
Where we're focusing as the resource grows, starting with oncology.
Oncology
solid & haematological tumours, with tumour–normal pairs and treatment outcomes.
Cardiometabolic
diabetes, coronary disease and lipid disorders with longitudinal labs.
Neurological
epilepsy, Parkinson's and dementia, deeply phenotyped.
Rare & inherited
Mendelian and founder-effect conditions across communities.
Hepatic & GI
liver disease, pancreatitis and IBD with imaging.
Maternal & child
pregnancy, neonatal and paediatric cohorts.
The global landscape
Genomics is driving discovery. The maps are just incomplete.
The field's biggest engines (deCODE (Amgen), the Regeneron Genetics Center, 23andMe, UK Biobank and Nashville Biosciences) were built largely on European-ancestry populations, often from retrospective or consumer data. We fill the gap they can't: South Asian diversity, generated and linked at the point of care.
Dimension | Global population biobanks deCODE · Regeneron · 23andMe · UK Biobank · NashBio | Wellytics Discovery |
|---|---|---|
Ancestry represented | European-majority panels | South Asian, 4,600+ endogamous communities |
How the data is created | Retrospective or consumer enrolment | Generated in routine care, at the point of care |
Clinical linkage | Variable, often shallow | Patient-level, longitudinal, outcome-linked |
Freshness | Largely frozen at enrolment | Compounds with every visit |
Access model | Data export or licensing | Secure federated analysis (TRE) |
Start here
Be first to collaborate.
The federated TRE is launching soon. Register your interest and we'll scope a collaboration when it opens, your IP, our governed data.